On December 9, 2011 the Centers for Disease Control and Prevention (CDC) released recommendations on the use of a new treatment regimen for latent tuberculosis (TB) infection. CDC’s recommendations are a result of a recent large randomized control trial which found the 12-dose regimen to be as effective for preventing TB as other regimens. The new regimen is also more likely to be completed than the current U.S. standard regimen of 9 months of daily isoniazid given without directly observed therapy. Find out more details at from the CDC publication, Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection. MMWR 2011;60:1650-1653. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6048a3.htm?s_cid=mm6048a_w [1]
